Fig. 6: Saracatinib alleviates IMQ-induced psoriasiform dermatitis.
From: Saracatinib inhibits necroptosis and ameliorates psoriatic inflammation by targeting MLKL
A Schematic representation of the mice experiments for the Control, Saracatinib, IMQ and IMQ + Saracatinib groups (n = 10). Saracatinib: 20 mg/kg. B Representative images of the mice dorsal on day 7 (n = 10). C Daily quantitative records of PASI score (epidermal erythema, thickness, and scales) of mice dorsal skin (n = 10). D Representative H&E staining images of cross-sectional slices of the mice dorsal on day 7 (n = 9). Scale bar = 100 µm. E IL-23 and IL-17 mRNA expression levels in tissues were determined by quantitative real-time PCR analysis (n = 8). (F) The relative skin tissues were lysed. Protein levels of RIPK1, RIPK3, MLKL, p-MLKL, and GAPDH were determined by western blotting (n = 3 for control and saracatinib, n = 4 for IMQ and IMQ + Saracatinib). The intensities of the indicated protein expression levels were quantified by densitometry and plotted. *: p < 0.05, **: p < 0.01. Data are represented as mean ± SD. See also Figs. S9–S11.
